PanKind Australian Pancreatic Cancer Foundation Limited
Concentration RiskGiving Philosophy
PanKind believes in a 'fair fight' against pancreatic cancer, addressing inequities in research and care. Their approach involves driving systemic change by investing in cutting-edge scientific research for early detection and new treatments, providing evidence-based support resources, collaborating for advocacy, and raising national awareness. They operate with urgency, fostering global partnerships to amplify impact and ensure equitable access to life-saving treatments worldwide.
Tips for Applicants
Researchers interested in pancreatic cancer are encouraged to review Pankind's research strategy and apply for grants as outlined on their 'For researchers' section. The foundation prioritizes early detection breakthroughs and new treatment possibilities. Applicants should align with the mission to triple survival rates by 2030.
Programs & Opportunities (5)
In 2025, an Early Detection Grant was named the Marianne Allan Pancreatic Research Grant in honour of Marianne Allan, dedicated to helping improve outcomes through detecting pancreatic cancer earlier.
Research projects focusing on early detection, new treatments, tumour microenvironment, and clinical management of pancreatic cancer
This grant supports early-stage research to develop new treatments, diagnostics, or quality-of-care improvements for pancreatic cancer. It funds innovative ideas that have the potential to impact treatment or diagnostics, even without extensive preliminary supporting data.
This grant funds advanced research to fast-track new treatments from the lab to clinical application, driving real-world impact. It contributes to advancing the translation of promising therapies to clinical studies or practice.
This grant funds innovative research to improve early detection and diagnosis of pancreatic cancer by supporting feasibility and proof-of-concept studies. It supports established and/or early career Australian researchers to develop preliminary data and attract additional funding.
Financial History (7 years)
| Year | Revenue | Expenses | Assets | Surplus |
|---|---|---|---|---|
| 2023 | $4.3M | $3.8M | $4.4M | $495K |
| 2022 | $3.8M | $2.6M | $4.1M | $1.2M |
| 2021 | $1.9M | $2.4M | $3.6M | $-527,848 |
| 2020 | $2.2M | $2.2M | $3.5M | $-17,815 |
| 2019 | $1.1M | $982K | $3.8M | $129K |
| 2018 | $1.4M | $2.4M | $4.6M | $-1,016,046 |
| 2017 | $1.1M | $2.4M | $5.6M | $-1,186,434 |
Community Evidence
External EvidenceIdentity
- GS ID
- AU-ABN-22145513060
- ABN
- 22145513060
- Sector
- indigenous
- Website
- www.pankind.org.au
- Financial Year
- 2023
Focus Areas
Board & Leadership (9)
- Alan McArthurchair
- Christopher Baggoleydirector
- Daniel Shieldsdirector
- Kemmler Ralphdirector
- Marissa Rossidirector
- Michelle Stewartdirector
- Peter Flanagandirector
- Rohan Jeffsdirector
- WARWICK WHITEdirector
Financials
- Revenue
- $4.3M
- Assets
- $4.4M
Method
- Match Confidence
- registry
- Cross-references
- 2 datasets
- Match Key
- ABN
- Relationships
- 18
Matched by Australian Business Number (ABN) — high confidence. This entity was found across multiple government datasets using the same ABN.
Data Sources
JusticeHub
External LinkThis entity is also tracked in JusticeHub with 0 interventions and 0 evidence records.
External ecosystem profile linked from GrantScope for additional context. JusticeHub content is maintained separately.
View on JusticeHubLocation Intelligence
- Postcode
- 2088
- Locality
- Mosman - South
- Remoteness
- Major Cities of Australia
- SEIFA Disadvantage
- Decile 10/10
- LGA
- Mosman
- SA2 Region
- Mosman - South
- Entities in Area
- 281